Sep 25, 2023 · 30m · allin
All-In Summit: Gene therapy and a new era of medicine with Dr. Nicole Paulk
0:00 / 0:00
▶ Watch on YouTube →
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
At the All-In Summit, Dr. Nicole Paulk delivers a presentation on the evolution of viral gene therapy, detailing Siren Biotechnology's universal immuno-gene platform for cancer and future applications in human enhancement. She then joins a panel discussion to address the regulatory, financial, and manufacturing bottlenecks currently facing the biotechnology industry.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. The hosts hold 2.8% of the talking time here. How this is scored →
The hosts as informed peer 2.3 Guest teaching 1.5 Guest disagreement 0.3 The hosts pushing back 0.8
speaking balance: gold is the hosts, purple is the guest (3 minute bins)
Sharpest disagreement ▶ 19:50 Tempering regulatory optimism
Dr. Paulk firmly tempers expectations by highlighting that FDA paperwork alone takes 18 months and ethical boards won't permit clinical trials for non-disease enhancements.
Hardest push from the hosts ▶ 27:12 Refusing high-level macro talk for technical grillingChamath bypasses general macro fundraising questions to force the guest to address specific vector payload size constraints above 4 KB.
Biggest teaching moment ▶ 28:30 Clarifying gene editing vs gene transfer payload constraintsDr. Paulk corrects the assumption that size limits constrain all AAV therapies, clarifying that gene editing only requires delivering enzymatic tools rather than full gene sequences.
The host holds their own ▶ 27:12 Citing precise kilobase viral payload limitsChamath demonstrates host domain expertise by calling out the specific 4 KB payload boundary for AAV vectors and questioning how Siren handles non-SNP mutations.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | The hosts as informed peer | Guest teaching | Guest disagreement | The hosts pushing back | Why |
|---|---|---|---|---|---|---|
| The Three Eras of Modern Medicine and Programmable Biology | 0 | 0 | 0 | 0 | Monologue presentation by Dr. Paulk introducing the three eras of medicine and programmable biology. The host is not present during this monologue. | |
| Viral Allies: Repurposing Nature's Delivery Systems | 0 | 0 | 0 | 0 | Monologue presentation showing clinical video evidence of gene therapy curing childhood blindness. Host is completely absent during this segment. | |
| Current State of the Gene Therapy Pipeline | 0 | 0 | 0 | 0 | Monologue detailing Siren Biotechnology's universal gene therapy approach to cancer. The host does not speak in this segment. | |
| Preclinical Breakthroughs in Glioblastoma Brain Cancer | 0 | 0 | 0 | 0 | Monologue concluding preclinical glioblastoma results and introducing short-sleep DEC2 gene targets. Host is absent throughout. | |
| Future Horizons: Sleep, Rejuvenation, and Space Adaptation | 2 | 4 | 1 | 1 | Host opens panel Q&A asking about regulatory hurdles and approval timelines. Guest educates panel on FDA regulatory paperwork and the non-disease definition barrier for enhancements. | |
| Panel Discussion: Financial Bottlenecks and Manufacturing Scale | 5 | 3 | 0 | 1 | Host demonstrates solid knowledge of CAR-T and lentivirus manufacturing delays. Guest elaborates on capital hurdles and CDMO bioreactor backlogs. | |
| Panel Discussion: Human Enhancement and Superhuman Traits | 3 | 2 | 0 | 0 | Panelist asks about positive psychology and human enhancement traits. Guest enthusiastically discusses night vision and metabolic modifications in a collaborative tone. | |
| Panel Discussion: Biotech Capital Markets and AAV Payload Capacity | 8 | 3 | 1 | 4 | Chamath interrupts general funding discussion to challenge guest on AAV 4 KB payload limitations and point mutations, demonstrating high technical mastery. |
Statements from this episode (18)
Viral gene therapies can now treat more than single-gene disorders
“So historically, we have used these to treat single gene genetic disorders, but we can use these much more broadly now, and I'll share a little bit about that.”
Humira generated $21B annually as the most successful drug in 20 years
“This antibody sells on average a little over twenty one billion dollars worth of just that drug every single year and has been the most successful drug for the last 20 years.”
Dr. Nicole Paulk: The vast majority of viruses do not sicken humans
“The vast majority of viruses on the planet are very good at getting inside of you, but very few of them make you sick.”
Dr. Nicole Paulk: Viral gene therapy can completely cure inherited genetic blindness
“So we're able to completely cure blindness.”
Prediction: Every person alive today will eventually receive viral gene therapy
“I promise you, in your lifetime, no matter how old any of you are in this audience, in your lifetime you are going to receive a viral gene therapy as medicine.”
Traditional gene therapies take 10-15 years and up to $3B to develop
“So every gene therapy on the planet, all the ones on that bullseye I just showed you on the last slide, whether they're from academia, industry, big pharma, doesn't matter. Every one of those is bespoke and personalized for a single indication, so that virus t…”
Dr. Nicole Paulk: Every human develops single-cell tumors every single day
“Every single one of you in this audience has a tumor. You've had a tumor every single day of your life. It's usually a single cell. You often have many of them throughout your body.”
Siren Biotechnology's viral gene therapy effectively cured mice of brain cancer
“So we can massively improve the lifespans of these animals, and for all intents and purposes, cure these mice, ah, of brain cancer”
Siren Biotechnology plans human trials for brain cancer gene therapy in 2025
“And we're queuing up for a clinical trial in twenty-twenty-five. So we're excited to start our clinical trial in twenty-twenty-five”
DEC2 gene mutation allows some to feel rested on four hours' sleep
“These patients, again, single mutation, single gene, these patients only need four hours of sleep a night to be completely rested the same way that we have, ah, the need for eight to nine hours of sleep a night.”
Anti-aging rejuvenation gene therapies are likely five to ten years away
“We're probably five to 10 years out on being ready to do this, but this is absolutely coming in your lifetime. You could get a rejuvenation gene therapy.”
Siren Biotech faces 18 months of paperwork before Phase I cancer trials
“We could start our brain cancer clinical trial today, but we're looking at 18 months of paperwork in order to file to do that first phase one”
FDA blocks clinical trials for lifestyle gene therapies like aging or sleep
“The FDA only lets you queue up clinical trials to test drugs that are for diseases, but aging is not a disease state. Wanting to sleep fewer hours is not a disease state. Insomnia is, but wanting to just sleep fewer hours and be fully rested is not a disease s…”
Catalent Pharma has a 2.5-year waitlist for 5,000-liter viral bioreactors
“But viruses are still something, like, if I queue up the biggest CDMO in the world, Catalent Pharma and ask them to make us a 5000 liter bioreactor virus, they'll absolutely say yes, but they won't even touch it for two and a half years.”
Dr. Nicole Paulk: Giving humans biological night vision is scientifically possible today
“Oh, night vision is totally possible.”
A San Diego biotech company is developing gene therapy for baldness
“There's a gene therapy company in San Diego working on male pattern baldness.”